NNC0487-0111
Sponsors
Novo Nordisk A/S
Conditions
Diabetes MellitusDiabetes Mellitus, Type 2Heart FailureKnee Osteoarthritis (OA)ObesityObstructive Sleep ApnoeaOsteoarthritis, KneeOverweight
Phase 1
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
CompletedNCT06049329
Start: 2023-09-14End: 2023-12-15Updated: 2025-03-05
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
CompletedNCT06559527
Start: 2024-08-20End: 2025-03-05Updated: 2025-03-30
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing
CompletedNCT06820476
Start: 2025-02-09End: 2025-05-14Updated: 2025-08-20
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity
RecruitingNCT07508020
Start: 2026-03-30End: 2028-01-22Target: 120Updated: 2026-04-27
Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes
RecruitingNCT07535307
Start: 2026-04-10End: 2027-12-06Target: 80Updated: 2026-04-24
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
Not yet recruitingNCT07587710
Start: 2026-05-13End: 2027-12-01Target: 35Updated: 2026-05-14
Phase 2
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
CompletedNCT06064006
Start: 2023-09-15End: 2024-11-27Updated: 2025-11-19
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
CompletedCTIS2023-509412-28-00
Start: 2024-07-26End: 2025-10-08Target: 339Updated: 2025-11-24
Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
RecruitingNCT07339423
Start: 2026-02-24End: 2029-08-21Target: 1150Updated: 2026-05-13
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Not yet recruitingNCT07400107
Start: 2026-05-20End: 2029-01-26Target: 1000Updated: 2026-03-12
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
RecruitingNCT07481630
Start: 2026-04-13End: 2028-08-14Target: 400Updated: 2026-05-14
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
RecruitingNCT07503210
Start: 2026-04-21End: 2028-07-04Target: 600Updated: 2026-05-19
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
RecruitingNCT07509307
Start: 2026-04-20End: 2028-08-14Target: 400Updated: 2026-05-15
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
RecruitingNCT07533175
Start: 2026-04-13End: 2028-08-07Target: 630Updated: 2026-05-19
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Not yet recruitingNCT07567001
Start: 2026-05-11End: 2029-08-15Target: 5610Updated: 2026-05-05
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
RecruitingNCT07571109
Start: 2026-05-05End: 2028-08-21Target: 300Updated: 2026-05-22
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
RecruitingNCT07571005
Start: 2026-05-05End: 2028-10-04Target: 300Updated: 2026-05-22